Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System

被引：0
|
作者：
Moore, Kristin J. [1 ]
Engel-Nitz, Nicole M. [1 ]
McMahon, Peter [2 ]
Beal, Jason [2 ]
Jhaveri, Teraneh Z. [2 ]
Williamson, Mellissa [2 ]
Andrade, Katherine [1 ]
Landis, Christina [1 ]
Sadek, Islam [2 ]
Hogea, Cosmina [2 ]
机构：
[1] Optum, Eden Prairie, MN USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?
    Deveaux, Michelle
    Stahl, Maximilian
    Giri, Smith
    Wang, Rong
    Podoltsev, Nikolai A.
    Ma, Xiaomei
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [22] Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
    Zeidan, Amer M.
    Al-Kali, Aref
    Borate, Uma
    Cluzeau, Thomas
    DeZern, Amy E.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kobata, Krissy
    Lyons, Roger
    Platzbecker, Uwe
    Sallman, David A.
    Santini, Valeria
    Sanz, Guillermo
    Sekeres, Mikkael A.
    Wei, Andrew H.
    Xiao, Zhijian
    Van Hoef, Marlies
    Nourry-Boulot, Claire
    Sadek, Islam
    Bengoudifa, Bourras-Rezki
    Sachs, Carolin
    Sabo, John
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [23] Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients With Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Johnson, Lisa
    Zhang, Yajia
    Su-Feher, Linda
    Lee, Yeonju
    Sallman, David A.
    Asch, Adam S.
    Al Malki, Monzr M.
    Kim, Hyunjae Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S368 - S369
  • [24] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [25] SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) USING A UNITED STATES (US) ELECTRONIC MEDICAL RECORD (EMR)-BASED COHORT
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Seal, B.
    Ogbonnaya, A.
    Raju, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    LEUKEMIA RESEARCH, 2017, 55 : S84 - S84
  • [26] SYSTEMATIC REVIEW OF THERAPY USED IN HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Bell, J.
    Galaznik, A.
    Huelin, R.
    Stokes, M.
    Seal, B.
    Fram, R.
    Faller, D. V.
    LEUKEMIA RESEARCH, 2017, 55 : S80 - S81
  • [27] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
  • [28] Impact of Transformation to Acute Myeloid Leukemia (AML) on Overall Survival (OS) among Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the United States of America (USA)
    Kota, Vamsi
    Ogbonnaya, Augustina
    Farrelly, Eileen
    Schroader, Bridgette
    Kristo, Fjoralba
    Raju, Aditya
    Dalal, Mehul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S348 - S348
  • [29] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study
    Amitai, Irina
    Geddes, Michelle
    Zhu, Nancy
    Keating, Mary-Margaret
    Sabloff, Mitchell
    Christou, Grace
    Leber, Brian
    Khalaf, Dina
    Leitch, Heather A.
    St-Hilaire, Eve
    Finn, Nicholas
    Shamy, April
    Yee, Karen
    Storring, John
    Nevill, Thomas
    Delage, Robert
    Elemary, Mohamed
    Banerji, Versha
    Chodirker, Lisa
    Mozessohn, Lee
    Parmentier, Anne
    Siddiqui, Mohammed
    Mamedov, Alexandre
    Zhang, Liying
    Buckstein, Rena
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (02) : 319 - 324
12345